GLP-1 Receptor Agonist Market With Complete SWOT Analysis and Forecast to 2030

1
GLP-1 Receptor Agonist Market Trends, Size,
Share, Demands, Overview, Growth, Revenue and
Forecast to 2030
sales_at_delvens.com www.delvens.com
2

GLP-1 Receptor Agonist Market, By Drug Type
(Exenatide, Liraglutide, Dulaglutide,
Semaglutide, and others), Brand (Bydureon,
Victoza, Trulicity, Ozempic, and Others), Route
of Administration (Injectable, Oral
Formulations), Application (Type 2 Diabetes,
Obesity, and Others) and region (North America,
Europe, Asia-Pacific, Middle East and Africa and
South America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/glp1-recep
tor-agonist-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
Glucagon-like peptide-1 (GLP-1) receptor agonists
bind to GLP-1 receptors and activate them to
stimulate physiological processes in the body.
GLP-1 receptor agonists interact with GLP-1
receptors present in the pancreatic beta cells to
stimulate insulin secretion. Thus, GLP-1 receptor
agonists can be used for the treatment of
diabetes. The benefits of using GLP-1 receptor
agonists for the treatment of type-2 diabetes
include inhibition of glucagon production from
pancreatic alpha cells in case of high blood
sugar levels. Glucagon is a hormone responsible
for increasing the concentration of glucose in
the blood by stimulating the liver to convert
glycogen into glucose. Moreover, GLP-1 receptor
agonists can promote the proliferation of
pancreatic beta-cell and decrease their apoptosis
or cell death. Also, GLP-1 receptor agonists slow
down the emptying of gastric juices which leads
to the slow release of nutrients from the food,
thus it prevents the spiking of blood glucose
levels. GLP-1 receptor agonists can also be used
to treat several other conditions such as
obesity, liver cirrhosis, cardiovascular disease,
and others. Purchase this Report
https//www.delvens.com/checkout/glp1-receptor-ago
nist-market
sales_at_delvens.com
www.delvens.com
4
Key Findings
GLP-1 Receptor Agonist Market is segmented into
various segments such as drugs type, brand, route
of administration, application, and region The
Drug type Segment is further fragmented into
Exenatide, Liraglutide, Dulaglutide, Semaglutide,
and others. Semaglutide is expected to be the
fastest-growing segment in the GLP-1 receptor
agonist market, driven by its efficacy and
once-weekly dosing regimen. Exenatide and
liraglutide are also expected to grow steadily,
while dulaglutide and others may face some
competition from new entrants.  The Brand
Segment is further fragmented into Bydureon,
Victoza, Trulicity, Ozempic, and Others. Novo
Nordisk's semaglutide is expected to be the
fastest-growing brand in the GLP-1 receptor
agonist market, as it has shown superior efficacy
compared to other drugs in the class. Eli Lilly's
tripeptide and Chiasma's oral octreotide also
have the potential to disrupt the market, though
they are still in clinical trials.  The Route of
Administration Segments is further fragmented
into Injectable, Oral Formulations. The oral
GLP-1 receptor agonist segment is expected to be
the fastest-growing, as it offers greater
convenience and ease of use for patients.
However, injectable formulations will continue to
dominate the market, especially for patients with
more severe cases of diabetes and obesity.
sales_at_delvens.com
www.delvens.com
5
Key Findings
The market is also divided into various regions
such as North America, Europe, Asia-Pacific,
South America, and Middle East and Africa. North
America is estimated to account for the largest
market share during the forecast period. Inquire
Before Buying https//www.delvens.com/Inquire-bef
ore-buying/glp1-receptor-agonist-market
sales_at_delvens.com
www.delvens.com
6
Competitive Landscape

• Pfizer Inc.
• Amgen Inc.
• Innovent Biologics
• Jiangsu Hengrui Medicine Co.
• Sun Pharmaceuticals Industries Ltd.
• 9 Meters Biopharma, Inc.

• Eli Lilly and Company
• GlaxoSmithKline plc
• Novo Nordisk A/S
• PegBio Co., Ltd.
• AstraZeneca
• Intarcia Therapeutics, Inc.
• Amylin Pharmaceuticals, Inc.
• Sanofi
• Hanmi Pharm. Co., Ltd.

sales_at_delvens.com
www.delvens.com
7
Recent Developments
In May 2022, The US Food and Drug Administration
(FDA granted approval for Eli Lilly and Companys
Mounjaro (tripeptide) injection as an adjunct to
diet and exercise to enhance glycemic control in
adult patients with type 2 diabetes. A single
molecule, Mounjaro is a once-weekly
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptor agonist.  In July 2021, AstraZenecas
Bydureon BCise (exenatide extended-release), the
once-weekly injectable suspension has been
approved in the US for the treatment of type 2
diabetes (T2D) to improve glycemic control in
pediatric patients (10 to 17 years).
sales_at_delvens.com
www.delvens.com
8
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com